Lin Daniel W, Porter Michael, Montgomery Bruce
Department of Urology, Virginia Puget Sound Health Care System, University of Washington, Northwest Prostate Cancer Specialized Program of Research Excellence, Seattle, Washington, USA.
Cancer. 2009 Jul 1;115(13):2863-71. doi: 10.1002/cncr.24324.
Outcomes of treatment for young men compared with older men with prostate cancer are poorly defined outside of limited institutional series. In this study, the authors examined the association between age at diagnosis and grade, stage, treatment, and survival outcomes in men who were diagnosed during the era of prostate-specific antigen testing.
The National Cancer Institute's Surveillance, Epidemiology, and End Results database was used to identify men who were diagnosed with prostate cancer between 1988 and 2003. Men ages 35 years to 74 years were stratified by age at diagnosis to examine differences in tumor characteristics, treatment, and survival within each age group.
In total, 318,774 men ages 35 years to 74 years were identified who had been diagnosed with adenocarcinoma of the prostate between 1988 and 2003. The proportion of men aged < or =55 years at diagnosis increased over the study period from 2.3% between the years 1988 and 1991 to 9% between the years 2000 and 2003, and the median age at diagnosis decreased from 72 years in 1988 to 68 years in 2003. Younger men were diagnosed less frequently with organ-confined tumors (P < .001) but were less likely to be diagnosed with high-grade cancer (P < .001). Older men were more likely to receive no local therapy or external beam radiation than young men (P < .001 for trend). Among men who had tumors with a Gleason score between 5 and 7, overall survival was worse with advancing age. However, among all age groups with high grade and stage, the youngest men (ages 35-44 years) were at the highest risk of all-cause and cancer-specific death.
Age at diagnosis among men with prostate cancer continued to decline. Younger men were more likely to undergo prostatectomy, have lower grade cancer, and, as a group, to have better overall and equivalent cancer-specific survival at 10 years compared with older men. Among men with high grade and locally advanced prostate cancer, the youngest men had a particularly poor prognosis compared with older men.
在有限的机构系列研究之外,前列腺癌年轻男性与老年男性的治疗结果尚不明确。在本研究中,作者探讨了在前列腺特异性抗原检测时代被诊断出前列腺癌的男性患者,其诊断时年龄与肿瘤分级、分期、治疗及生存结果之间的关联。
利用美国国立癌症研究所的监测、流行病学和最终结果数据库,识别出1988年至2003年间被诊断为前列腺癌的男性。将年龄在35岁至74岁之间的男性按诊断时年龄分层,以研究各年龄组在肿瘤特征、治疗和生存方面的差异。
总共识别出318,774名年龄在35岁至74岁之间、于1988年至2003年间被诊断为前列腺腺癌的男性。在研究期间,诊断时年龄≤55岁的男性比例从1988年至1991年的2.3%增至2000年至2003年的9%,诊断时的中位年龄从1988年的72岁降至2003年的68岁。年轻男性被诊断为器官局限性肿瘤的频率较低(P<.001),但被诊断为高级别癌症的可能性较小(P<.001)。老年男性比年轻男性更有可能未接受局部治疗或外照射放疗(趋势P<.001)。在Gleason评分在5至7分之间的男性中,总体生存率随年龄增长而降低。然而,在所有高级别和高分期的年龄组中,最年轻的男性(35至44岁)全因死亡和癌症特异性死亡风险最高。
前列腺癌男性的诊断年龄持续下降。与老年男性相比,年轻男性更有可能接受前列腺切除术,患低级别癌症,且总体而言,10年时具有更好的总体生存率和相当的癌症特异性生存率。在患有高级别和局部晚期前列腺癌的男性中,最年轻的男性与老年男性相比预后特别差。